Wedbush reaffirmed their outperform rating on shares of Obseva (NASDAQ:OBSV) in a research note published on Thursday, RTT News reports. Wedbush currently has a $38.00 target price on the stock.
Several other equities research analysts have also issued reports on the company. Zacks Investment Research upgraded York Water from a sell rating to a hold rating in a report on Saturday, June 1st. ValuEngine lowered Valero Energy from a hold rating to a sell rating in a report on Wednesday, May 8th. Finally, HC Wainwright reiterated a buy rating on shares of Zomedica Pharmaceuticals in a report on Wednesday, June 5th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $29.80.
NASDAQ:OBSV opened at $10.05 on Thursday. The business’s 50-day moving average price is $11.08. Obseva has a 52-week low of $9.19 and a 52-week high of $19.40. The company has a current ratio of 6.73, a quick ratio of 6.73 and a debt-to-equity ratio of 0.02.
Several institutional investors have recently made changes to their positions in OBSV. United Services Automobile Association grew its holdings in Obseva by 132.3% during the fourth quarter. United Services Automobile Association now owns 26,480 shares of the company’s stock worth $335,000 after acquiring an additional 15,080 shares during the period. Dimensional Fund Advisors LP boosted its position in Obseva by 274.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 70,573 shares of the company’s stock valued at $893,000 after purchasing an additional 51,733 shares during the last quarter. Geode Capital Management LLC acquired a new position in Obseva during the fourth quarter valued at approximately $159,000. Barclays PLC boosted its position in Obseva by 331.1% during the fourth quarter. Barclays PLC now owns 10,118 shares of the company’s stock valued at $128,000 after purchasing an additional 7,771 shares during the last quarter. Finally, Weiss Multi Strategy Advisers LLC lifted its position in shares of Obseva by 4.5% in the fourth quarter. Weiss Multi Strategy Advisers LLC now owns 21,000 shares of the company’s stock valued at $266,000 after buying an additional 905 shares during the last quarter. Institutional investors and hedge funds own 63.58% of the company’s stock.
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Further Reading: Coverage Ratio
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.